- Home
- BOLD vs VIVO Comparison
BOLD vs VIVO Comparison
Compare BOLD & VIVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BOLD | VIVO |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Power Generation |
| Sector | | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 37.5M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | BOLD | VIVO |
|---|---|---|
| Price | $1.42 | $4.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 129.1K | ★ 2.2M |
| Earning Date | 05-06-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $1.97 |
| 52 Week High | $1.68 | $6.86 |
Technical Indicators
Market Signals| Indicator | BOLD | VIVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 50.04 |
| Support Level | $1.40 | $4.17 |
| Resistance Level | $1.53 | $5.25 |
| Average True Range (ATR) | 0.06 | 0.81 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 26.92 | 17.84 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.